ArticleBioengineering (Basel, Switzerland)2025
Composites of Reduced Graphene Oxide Based on Silver Nanoparticles and Their Effect on Breast Cancer Stem Cells.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Layers of Hope: How Graphene and Nanostructures Hold Promise for Cancer Therapy.International journal of molecular sciences · 2026Review
- Silver Nanoparticles as Anticancer Agents: Mechanisms Insight, Current Studies, and Limitations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Silver integrated hybrids and nanocomposites for next-generation biomedicine: Beyond antimicrobial coatings toward smart sense-response-heal platforms.Materials today. Bio · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graphene and its related nanocomposites have garnered significant interest due to their distinct physiochemical and biological properties. In this study, reduced graphene oxide-silver hybrid nanostructures were synthesized for applications in biomedical nanotechnology, particularly in targeting cancer stem cells (CSCs). A range of analytical techniques, such as X-ray diffraction (XRD), Raman spectroscopy, Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and UV-visible absorption spectroscopy (UV-VIS), were employed to characterize graphene oxide (GO), reduced graphene oxide (rGO)-silver nanoparticles (AgNPs), and their composite structures. The GO-rGO-AgNPs exhibited potent anticancer properties as evidenced by cell culture assays, spheroid formation assay, and quantitative RT-PCR analysis. Treatment of breast cancer cells (MCF-7) with GO, rGO, and AgNPs significantly reduced cell proliferation and mammosphere formation. Furthermore, these treatments downregulated the expression of marker genes associated with CSCs in MCF-7 cells. Among the tested materials, rGO-AgNP, sodium citrate-mediated GO-AgNP, and rGO-AgNP nanocomposites demonstrated superior inhibitory effects on cell survival compared to GO alone. These findings suggest that these nanocomposites hold promise as effective and non-toxic therapeutic agents for targeting cancer cells and CSCs, thereby offering a novel approach to cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.